Trending News

WASHINGTON, Dec. 3, 2018 /PRNewswire/ -- Vanda PharmaceuticalsInc. (Vanda) VNDA, +1.66% today announced that tradipitant met the primary endpoint in VLY686-2301, a Phase II clinical study in patients with idiopathic and diabetic gastroparesis. The study also showed that tradipitant was well tolerated with comparable rates of

Shionogi Receives Positive Opinion for Rizmoic (naldemedine) in Latest Announcement from the Committee for Medicinal Products for Human Use (CHMP) OSAKA, Japan, and LONDON, UK, 18 December 2018 - Shionogi & Co., Ltd. (hereafter "Shionogi"), a research-driven pharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Intended for U.S. Audience FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) -- Unlike other prescription CIC treatments, Motegrity works differently by enhancing natural movements of the colon muscle, known as peristalsis1,2 -- Motegrity was shown to help normalize complete spontaneous...